# Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

> **NCT01764945** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 201335 (Reference)
- **DRUG:** BI 201335 (Test)
- **DRUG:** BI 201335 (Test)
- **DRUG:** BI 201335 (Test)
- **DRUG:** BI 201335 (Reference)
- **DRUG:** BI 201335 (Test)
- **DRUG:** BI 201335 (Test)
- **DRUG:** BI 201335 (Test)

## Key facts

- **NCT ID:** NCT01764945
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2015-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01764945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01764945, "Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01764945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*